Lynx1 Capital Management LP bought $4,114 of TCRX
owner at TScan Therapeutics, Inc.. 947 shares at an average of $4.34, traded Nov 15, 2024, filed Nov 19, 2024.
Score components
- +12Role10% owner
- 0Trade size$4k at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -30.4%, 3m -52.3%, 6m -71.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-24-006718, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | POpen-market purchase Common stock, $0.0001 par value per shareindirect: See footnote | +947 | $4.34 | $4,114 | 5,225,547 | Nov 19, 2024 |
Related signals
Other insiders at TScan Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $3.1M 2,588,794 shares | +48% | |
| 28Weak | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $386k 131,800 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.